- Home
- TIL vs VTYX Comparison
TIL vs VTYX Comparison
Compare TIL & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- VTYX
- Stock Information
- Founded
- TIL 2018
- VTYX 2018
- Country
- TIL United States
- VTYX United States
- Employees
- TIL N/A
- VTYX N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TIL Health Care
- VTYX Health Care
- Exchange
- TIL Nasdaq
- VTYX Nasdaq
- Market Cap
- TIL 177.1M
- VTYX 154.9M
- IPO Year
- TIL 2021
- VTYX 2021
- Fundamental
- Price
- TIL $15.16
- VTYX $8.09
- Analyst Decision
- TIL Strong Buy
- VTYX Buy
- Analyst Count
- TIL 5
- VTYX 3
- Target Price
- TIL $100.67
- VTYX $12.50
- AVG Volume (30 Days)
- TIL 82.0K
- VTYX 9.8M
- Earning Date
- TIL 11-13-2025
- VTYX 11-06-2025
- Dividend Yield
- TIL N/A
- VTYX N/A
- EPS Growth
- TIL N/A
- VTYX N/A
- EPS
- TIL N/A
- VTYX N/A
- Revenue
- TIL N/A
- VTYX N/A
- Revenue This Year
- TIL N/A
- VTYX N/A
- Revenue Next Year
- TIL N/A
- VTYX N/A
- P/E Ratio
- TIL N/A
- VTYX N/A
- Revenue Growth
- TIL N/A
- VTYX N/A
- 52 Week Low
- TIL $10.80
- VTYX $0.78
- 52 Week High
- TIL $42.79
- VTYX $9.50
- Technical
- Relative Strength Index (RSI)
- TIL 34.33
- VTYX 76.14
- Support Level
- TIL $18.10
- VTYX $5.75
- Resistance Level
- TIL $20.11
- VTYX $9.50
- Average True Range (ATR)
- TIL 1.37
- VTYX 0.78
- MACD
- TIL -0.25
- VTYX 0.33
- Stochastic Oscillator
- TIL 0.00
- VTYX 76.85
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.